- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02582216
3D Augmented Reality Mirror Visual Feedback Applied to the Treatment of Unilateral Upper Extremity Neuropathic Pain.
3D Augmented Reality Mirror Visual Feedback Therapy Applied to the Treatment of Persistent, Unilateral Upper Extremity Neuropathic Pain: A Preliminary Study
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Neuropathic pain in the unilateral upper extremity scored by DN4 questionnaire
- At least 3 months symptom duration following injury
- Minimum pain of 40 on a visual analogue scale (VAS);
- A drug treatment regimen that was stable for at least 2 weeks.
- Subjects were allowed to participate if they presented with any of the following: (1) A CRPS diagnosis, in accordance with the International Association for the Study of Pain criteria, Phantom Limb Pain (PLP), or spinal cord injury or plexopathy; and (2) an history of being treated before by conventional mirror therapy but, in their case, the mirror therapy failed.
Exclusion Criteria:
- Bilateral injury,
- Patients with epilepsy
- Side effects known to 3D (such as nausea, cephalalgia)
- Cognitive disorder
- Poor knowledge of the French language.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Open label
3D augmented reality
|
Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures.
The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis.
This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain on the Visual Analog Scale (VAS)
Time Frame: baseline and week
|
Visual Analogic Scale assessed pain intensity before and after the intervention.
Possible scores range from 0 (no pain) to 10 (worst possible pain)
|
baseline and week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neuropathic Pain Assessed With DN4 Questionnaire
Time Frame: 1 week
|
DN4 (Douleur Neuropathique en 4 Questions) is a screening tool for neuropathic pain consisting of interview questions (DN4-interview) and physical tests. When the practitioner suspects neuropathic pain, the DN4 questionnaire is useful as a diagnostic tool. This questionnaire is divided into 4 questions representing 10 check items:
If the patient's score is 4/10 or more, the test is positive (sensitivity at 82.9%; specificity at 89.9%) Dn4 questionnaire were completed before and 24 hour after the last session |
1 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaire de Saint-Antoine
Time Frame: 1 week
|
French adaptation of Melzack's MC Gill Pain Questionnaire (MPQ). It is a questionnaire of 61 qualifying words divided into 17 subclasses: 9 sensory, 7 emotional, 1 evaluative. The patient is asked to select the adjectives and then rate them from 0 (not at all) to 4 (extremely). This self-assessment scale allows clinical practice to specify the participation of the sensory and the emotional in pain intensity. self-questionnaire scoring the sensory and emotional qualities of the pain |
1 week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kine-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuralgia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPost Herpetic NeuralgiaUnited States, Colombia, South Africa, Hong Kong, Ukraine, Bulgaria, Croatia, India, Sweden, Czechia, Denmark, Germany, Poland, Russian Federation, Serbia, Slovakia, Taiwan
-
Bial - Portela C S.A.Terminated
-
Odense University HospitalCompletedPost Herpetic NeuralgiaDenmark
-
DepomedCompletedPost Herpetic NeuralgiaUnited States
-
PfizerCompletedPostherpetic NeuralgiaUnited States
-
Yonsei UniversityWithdrawnThe Evaluation of Erector Spinae Plane Block for the Pain Control of Thoracic Postherpetic NeuralgiaThoracic Postherpetic NeuralgiaKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia ( PHN )China
-
Bial - Portela C S.A.Completed
-
Grünenthal GmbHCompletedPost Herpetic Neuralgia
-
Novartis PharmaceuticalsTerminatedPost-herpetic NeuralgiaAustralia, Taiwan, Germany, France, Portugal, Czechia, United Kingdom, Hungary, Spain, Slovakia, Japan, Canada, Denmark, Norway, Austria, Belgium, Poland, Italy, Korea, Republic of
Clinical Trials on 3D augmented reality
-
H. Lee Moffitt Cancer Center and Research InstituteNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Seif El-Din Amr Hussein HegabNot yet recruiting
-
University of PittsburghNortheastern University; NSFRecruiting
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedCentral Line ComplicationCanada
-
Chinese University of Hong KongNot yet recruiting
-
Stanford UniversityCompletedAcute Pain | Mobility Limitation | Spinal FusionUnited States
-
Brigham and Women's HospitalWithdrawnPain | Infection | MalignancyUnited States
-
University of VirginiaRecruitingPain, Acute | Vocal Cord Paralysis | Laryngeal Neoplasms | Vocal Fold PolypUnited States
-
Wayne State UniversityEnrolling by invitationSpecific Phobia, AnimalUnited States
-
Universidad Peruana Cayetano HerediaCompletedHospitalized ChildPeru